Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation Therapy.

PURPOSE To evaluate whether inclusion of incidental radiation dose to the cardiac atria and ventricles improves the prediction of grade ≥3 radiation pneumonitis (RP) in advanced-stage non-small cell lung cancer (AS-NSCLC) patients treated with intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT). METHODS AND MATERIALS Using a bootstrap modeling approach, clinical parameters and dose-volume histogram (DVH) parameters of lungs and heart (assessing atria and ventricles separately and combined) were evaluated for RP prediction in 188 AS-NSCLC patients. RESULTS After a median follow-up of 18.4 months, 26 patients (13.8%) developed RP. Only the median mean lung dose (MLD) differed between groups (15.3 Gy vs 13.7 Gy for the RP and non-RP group, respectively; P=.004). The MLD showed the highest Spearman correlation coefficient (Rs) for RP (Rs = 0.21; P<.01). Most Rs of the lung DVH parameters exceeded those of the heart DVH parameters. After predictive modeling using a bootstrap procedure, the MLD was always included in the predictive model for grade ≥3 RP, whereas the heart DVH parameters were seldom included in the model. CONCLUSION Incidental dose to the cardiac atria and ventricles did not improve RP risk prediction in our cohort of 188 AS-NSCLC patients treated with IMRT or VMAT.

[1]  Jeffrey D Bradley,et al.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. , 2013, International journal of radiation oncology, biology, physics.

[2]  L. de Geus-Oei,et al.  Comparison of toxicity and outcome in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy using IMRT or VMAT. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  J. Deasy,et al.  Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. , 2006, International journal of radiation oncology, biology, physics.

[4]  Aamer Chughtai,et al.  Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. , 2011, International journal of radiation oncology, biology, physics.

[5]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[6]  Esther G C Troost,et al.  Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Johannes A Langendijk,et al.  The impact of heart irradiation on dose-volume effects in the rat lung. , 2007, International journal of radiation oncology, biology, physics.

[8]  Benjamin Movsas,et al.  Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. , 2011, International journal of radiation oncology, biology, physics.

[9]  R. D. de Boer,et al.  Physiological interaction of heart and lung in thoracic irradiation. , 2012, International journal of radiation oncology, biology, physics.

[10]  Jinming Yu,et al.  Early detection of radiation-induced heart disease using (99m)Tc-MIBI SPECT gated myocardial perfusion imaging in patients with oesophageal cancer during radiotherapy. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Georgi Nalbantov,et al.  Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  R. Mohan,et al.  Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort , 2014, Acta oncologica.

[13]  J. Dang,et al.  Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy , 2013, Acta oncologica.

[14]  I El Naqa,et al.  Dose response explorer: an integrated open-source tool for exploring and modelling radiotherapy dose–volume outcome relationships , 2006, Physics in medicine and biology.

[15]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Vogelius,et al.  A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis , 2012, Acta oncologica.

[17]  Issam El Naqa,et al.  Heart irradiation as a risk factor for radiation pneumonitis , 2011, Acta oncologica.

[18]  M. Martel,et al.  Radiation dose-volume effects in the lung. , 2010, International journal of radiation oncology, biology, physics.

[19]  J. Deasy,et al.  Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. , 2006, International journal of radiation oncology, biology, physics.

[20]  R. Fisher,et al.  Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. , 2005, International Journal of Radiation Oncology, Biology, Physics.